Catálogo de publicaciones - revistas
European Journal of Heart Failure
Resumen/Descripción – provisto por la editorial
No disponible.
Palabras clave – provistas por la editorial
No disponibles.
Disponibilidad
Institución detectada | Período | Navegá | Descargá | Solicitá |
---|---|---|---|---|
No detectada | desde ene. 1999 / hasta dic. 2023 | Wiley Online Library |
Información
Tipo de recurso:
revistas
ISSN impreso
1388-9842
ISSN electrónico
1879-0844
País de edición
Estados Unidos
Cobertura temática
Tabla de contenidos
doi: 10.1002/ejhf.2946
Heart Failure Diagnosis in the General Community ‐ Who, How and When? A clinical consensus statement of the Heart Failure Association (HFA ) of the ESC
Kieran F. Docherty; Carolyn S.P. Lam; Amina Rakisheva; Andrew J.S. Coats; Trisha Greenhalgh; Marco Metra; Mark C. Petrie; Giuseppe M.C. Rosano
Palabras clave: Cardiology and Cardiovascular Medicine.
Pp. No disponible
doi: 10.1002/ejhf.3030
Using combinational diuretics across the spectrum of renal function
Pieter Martens; Wilfried Mullens
Palabras clave: Cardiology and Cardiovascular Medicine.
Pp. No disponible
doi: 10.1002/ejhf.2979
State‐of‐the‐art document on optimal contemporary management of cardiomyopathies
Petar M. Seferović; Marija Polovina; Giuseppe Rosano; Biykem Bozkurt; Marco Metra; Stephane Heymans; Wilfried Mullens; Johann Bauersachs; Karen Sliwa; Rudolf A. de Boer; Dimitrios Farmakis; Thomas Thum; Iacopo Olivotto; Claudio Rapezzi; Aleš Linhart; Domenico Corrado; Carsten Tschöpe; Ivan Milinković; Antoni Bayes Genis; Gerasimos Filippatos; Andre Keren; Milika Ašanin; Gordana Krljanac; Ružica Maksimović; Hadi Skouri; Tuvia Ben Gal; Brenda Moura; Maurizio Volterrani; Magdy Abdelhamid; Yuri Lopatin; Ovidiu Chioncel; Andrew J.S. Coats
<jats:title>Abstract</jats:title><jats:p>Cardiomyopathies represent significant contributors to cardiovascular morbidity and mortality. Over the past decades, a progress has occurred in characterization of the genetic background and major pathophysiological mechanisms, which has been incorporated into a more nuanced diagnostic approach and risk stratification. Furthermore, medications targeting core disease processes and/or their downstream adverse effects have been introduced for several cardiomyopathies. Combined with standard care and prevention of sudden cardiac death, these novel and emerging targeted therapies offer a possibility of improving the outcomes in several cardiomyopathies. Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence‐based novel therapeutic concepts and established principles of care, tailored to the individual patient aetiology and clinical presentation of the cardiomyopathy. The scope of the document encompasses contemporary treatment of dilated, hypertrophic, restrictive and arrhythmogenic cardiomyopathy. It was based on an expert consensus reached at the Heart Failure Association online Workshop, held on 18 March 2021.</jats:p>
Palabras clave: Cardiology and Cardiovascular Medicine.
Pp. No disponible